Clinical Trials Logo
  1. Home
  2. Hypothalamic Obesity
  3. NCT06046443

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Hypothalamic Obesity Clinical Trial

Official title:
A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension

Clinical Trial Summary

The goal of this trial is to determine the effect of LB54640 on weight reduction, hunger, and quality of life in patients 12 years of age and older with Hypothalamic Obesity (HO). To determine how well LB54640 works and how safe it is, patients with HO will take a daily dosing of either LB54640 or placebo and complete trial assessments for up to 56 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06046443
Study type Interventional
Source LG Chem
Contact LG CHEM
Phone +82-2-3777-1114
Email pathway@lgchem.com
Status Not yet recruiting
Phase Phase 2
Start date December 31, 2023
Completion date March 31, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT02849743 - Intranasal Oxytocin in Hypothalamic Obesity Phase 2
Recruiting NCT06217848 - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Early Phase 1
Withdrawn NCT05147415 - Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Phase 2
Completed NCT00892073 - Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Phase 2
Not yet recruiting NCT06299891 - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phase 2
Recruiting NCT06239116 - A Study of RM-718 in Healthy Subjects and in Patients With HO Phase 1
Completed NCT02664441 - Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Phase 3
Completed NCT04725240 - Open-Label Study of Setmelanotide in Hypothalamic Obesity Phase 2
Completed NCT03673813 - A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Withdrawn NCT03708913 - Neuromodulation for Hypothalamic Obesity N/A
Completed NCT01061775 - Effects of Exenatide on Hypothalamic Obesity Phase 1/Phase 2
Completed NCT02860923 - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Phase 3
Completed NCT00171613 - A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Phase 4
Recruiting NCT01783717 - Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage N/A
Enrolling by invitation NCT05774756 - A Trial of Setmelanotide in Acquired Hypothalamic Obesity Phase 3
Completed NCT05319301 - Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) N/A